Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) May 01, 2014

Intranasal Capsaicin (IC) Rapidly Relieves the Pain of Migraine and Other Severe Headaches (P7.179)

Maria Alexianu, Anjan Chatterjee
First published April 9, 2014,
Maria Alexianu
1Neurology Overlook Hospital Summit NJ United States
2Summit Neurology Consulting Summit NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anjan Chatterjee
3VR1 Inc New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Intranasal Capsaicin (IC) Rapidly Relieves the Pain of Migraine and Other Severe Headaches (P7.179)
Maria Alexianu, Anjan Chatterjee
Neurology Apr 2014, 82 (10 Supplement) P7.179;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: Thirteen patient case-series treated with intranasal capsaicin (IC) for migraines, cluster headache and other severe frequent headaches. BACKGROUND: Intranasal Capsaicin (IC) administration is hypothesized to cause analgesia by calcium-mediated desensitization of the trigemino-vascular system. Effective for migraines and cluster headaches, IC has not been described in the treatment of other types of severe headaches. Less well understood is the natural history of treatment response and time to symptom relief. DESIGN/METHODS: Thirteen patients (6 men), ages 28-65, with headaches, (migraines without aura [6], cluster headache [1], post-traumatic headache [1], tension headache [4], medication overuse headache [1]) and related moderate to severe functional disability, were treated with IC. Current medications included naproxen, piroxicam, butalbital, sumatriptan, eletriptan, rizatriptan, verapamil, oxygen and prednisone (Cluster Headache). Post informed consent, an index episode of headache was treated with IC (50 μL, ipsilateral nose) without the use of concomitant medicine. Patients were instructed to use IC as early as possible, allowed to use repeat doses prn, and were asked to report efficacy (five point scale from no relief [1+] to complete pain relief [5+]), tolerability, and time to analgesia. RESULTS: Nine patients had complete (5+) pain relief, one reported (4+), two reported (3+) and one (2+) relief. All patients reported onset of relief in less than a minute post-dose and maximal analgesia inside of 3 minutes. Relief duration ranged from 30 minutes (cluster headache) to several hours. Adverse events included nasal sting (13/13), lacrimation (13/13) and sneezing (4/13). Sting intensity was rated as severe/prolonged in 3/13 patients. Sting duration ranged from 2 to 10 minutes. One patient declined IC for subsequent headaches due to low perceived efficacy. Subsequent dosing in twelve patients did not change the efficacy/tolerability parameters reported. CONCLUSIONS: IC may be an option for rapid analgesia in a range of headache disorders. Nasal sting was not a deterrent for use if IC was perceived effective. Study Supported by: VR1 Inc.

Disclosure: Dr. Alexianu has nothing to disclose. Dr. Chatterjee has received personal compensation for activities with VR1 Inc. as an employee. Dr. Chatterjee holds stock and/or stock options in VR1 Inc., which sponsored research in which Dr. Chatterjee was involved as an investigator.

Thursday, May 1 2014, 3:00 pm-6:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise